Diagnostic Utility of PRAME Immunohistochemistry for Distinguishing Acral Melanoma From Acral Melanocytic Nevi
Journal of Cutaneous Pathology · 2026-12 · 53 (12) · 1148-1158
DOI: 10.1111/cup.70163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cutaneous Pathology, online erschienen am 17.06.2026. Verfasst von Kritsada Phatcharamaneepakorn und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Nevus, Pigmented, Antigens, Neoplasm, Melanoma, Skin Neoplasms. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Siriraj Research Development Fund, Prasert Prasarttong-Osoth Grant.
Abstract (Originalsprache)
Introduction
Preferentially expressed antigen in melanoma (PRAME) immunohistochemistry helps distinguish non‐acral melanocytic lesions, but few studies have addressed its value in acral lesions. We aimed to identify an optimal PRAME cut‐off score to differentiate acral melanoma (AM) from acral melanocytic nevi (AMN).
Methods
Formalin‐fixed, paraffin‐embedded specimens of AM, AMN, and small biopsy of atypical melanocytic lesions (AMLs) were included. PRAME staining was performed. Expression was categorized into five groups: 0 (0%), 1+ (1%–25%), 2+ (26%–50%), 3+ (51%–75%), and 4+ (> 75%). PRAME nuclear expression was compared between AM and AMN to identify the best cut‐off score, which was then assessed in small‐sized biopsies of AML specimens.
Results
We analyzed 62 AMs, 62 AMNs, and 23 AMLs. A PRAME score of ≥ 3+ optimally differentiated AM from AMN (sensitivity 80.6%, specificity 98.4%, positive predictive value 98%, and negative predictive value 83.6%). PRAME expression score ≥ 3+ was strongly associated with AM, whereas AMN showed expression score < 3+ ( p < 0.001). However, one AM was completely negative for PRAME, and one AMN exhibited strong PRAME staining.
Conclusions
PRAME immunohistochemistry with a cut‐off of ≥ 3+ is useful for differentiating AM from AMN. However, false positivity and negativity of PRAME expression must be considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Division of Plastic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Kritsada Phatcharamaneepakorn, Panitta Sitthinamsuwan, Penvadee Pattanaprichakul
Förderung
- The Siriraj Research Development Fund
- Prasert Prasarttong-Osoth Grant
Zitieren
APA
Phatcharamaneepakorn, K., Sitthinamsuwan, P., Pattanaprichakul, P., Chairatchaneeboon, M., & Yodrabum, N. (2026). Diagnostic Utility of PRAME Immunohistochemistry for Distinguishing Acral Melanoma From Acral Melanocytic Nevi. Journal of Cutaneous Pathology, 53(12), 1148-1158. https://doi.org/10.1111/cup.70163
Vancouver
Phatcharamaneepakorn K, Sitthinamsuwan P, Pattanaprichakul P, Chairatchaneeboon M, Yodrabum N. Diagnostic Utility of PRAME Immunohistochemistry for Distinguishing Acral Melanoma From Acral Melanocytic Nevi. Journal of Cutaneous Pathology. 2026;53(12):1148-1158. doi:10.1111/cup.70163
BibTeX
@article{Phatcharamaneepakorn2026,
author = {Phatcharamaneepakorn, Kritsada and Sitthinamsuwan, Panitta and Pattanaprichakul, Penvadee and Chairatchaneeboon, Manasmon and Yodrabum, Nutcha},
title = {Diagnostic Utility of PRAME Immunohistochemistry for Distinguishing Acral Melanoma From Acral Melanocytic Nevi},
journal = {Journal of Cutaneous Pathology},
year = {2026},
volume = {53},
number = {12},
pages = {1148--1158},
doi = {10.1111/cup.70163}
}
EUVIMED